TY - JOUR T1 - Postoperative 5-FU based Radiochemotherapy in Rectal Cancer: Retrospective Long Term Results and Prognostic Factors of a Pooled Analysis on 1,338 Patients JF - Anticancer Research JO - Anticancer Res SP - 4557 LP - 4566 VL - 33 IS - 10 AU - DOMENICO GENOVESI AU - ROBERT J. MYERSON AU - GIAMPIERO AUSILI CÈFARO AU - ANNAMARIA VINCIGUERRA AU - ANTONIETTA AUGURIO AU - MARIANNA TRIGNANI AU - MONICA DI TOMMASO AU - MARIANNA NUZZO AU - MARCO LUPATTELLI AU - CYNTHIA ARISTEI AU - RITA BELLAVITA AU - LUCIANO SCANDOLARO AU - DORIAN COSENTINO AU - GIUSEPPE PANI AU - LUIGI ZICCARELLI AU - MARIA A. GAMBACORTA AU - MARIA C. BARBA AU - ERNESTO MARANZANO AU - FABIO TRIPPA AU - PIERA SCIACERO AU - RITA NIESPOLO AU - CRISTINA LEONARDI AU - TIZIANA IANNONE AU - MARIA ELENA ROSETTO AU - VINCENZO FUSCO AU - PIERO SANPAOLO AU - ANTONELLA MELANO AU - FRANCESCA VALVO AU - CARLO CAPIRCI AU - ANTONINO DE PAOLI AU - MARTA DI NICOLA AU - GIOVANNA MANTELLO AU - VINCENZO VALENTINI AU - ON BEHALF OF THE G.I. A.I.R.O. WORKING GROUP Y1 - 2013/10/01 UR - http://ar.iiarjournals.org/content/33/10/4557.abstract N2 - Aim: To evaluate survival outcomes of patients in pStage II-III rectal cancer treated with adjuvant 5-fluorouracil-based radiochemotherapy and toretrospectively analyzethe impact of prognostic variables on local control, metastasis-free survival and cause-specific survival. Patients and Methods: A total of 1,338 patients, treated between 1985-2005 for locally advanced rectal cancer, who underwent surgery and postoperative 5-fluorouracil-based chemoradiation, were selected. Results: The actuarial 5- and 10-year outcomes were: local control 87.0%-84.1%, disease-free survival 61.6%-52.1%, metastasis-free survival 72.0%-67.2%, cause-specific survival 70.4%-57.5%, and overall survival 63.8%-53.4%. Better outcomes were observed in patients with IIA, IIIA stage. Multivariate analyses showed that variables significantly affecting metastasis-free survival were pT4 and pN2, while for cancer-specific survival those variables were age >65 years, pT4, pN1, pN2, distal tumors and number of lymph nodes removed ≤12. Conclusion: This study confirmed that among stage II-III rectal cancer patients there are subgroups of patients with different clinical outcomes. ER -